Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 6/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437205 | 0.89 | GABRA5 (0.41) | KDM4EPKMGABRA5FFAR1 | |
| SCHEMBL17811682 | 0.86 | GABRA1 (0.31) | RXRAGRIN1GRIN2BFFAR1 | |
| SCHEMBL17811681 | 0.86 | RXRA (0.46) | RXRAGRIN1GRIN2B | |
| SCHEMBL17804272 | 0.85 | ACACB (0.36) | PPARGPKMGABRA5 | |
| SCHEMBL16439376 | 0.85 | NR1H4 (0.31) | RXRAGRIN1GRIN2B | |
| SCHEMBL16442855 | 0.85 | ALDH1A1 (0.39) | KDM4EALDH1A1HSD17B10PKM | |
| SCHEMBL17811666 | 0.84 | PPARG (0.34) | RXRAGRIN1GRIN2BPPARGPKM | |
| SCHEMBL17811680 | 0.84 | PKM (0.32) | PKMKDM1AFFAR1 | |
| SCHEMBL17796906 | 0.83 | PPARG (0.35) | RXRAGRIN1GRIN2BPPARGGABRA5 | |
| SCHEMBL17804259 | 0.82 | BRD9 (0.33) | PKMGABRA5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9521848-B2 | Tetrazolinone compound and use therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | CYP51A1, CYP4F11, CYP1B1 | KDM4E 2743/4885ALDH1A1 811/4885HSD17B10 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.